Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
Primary Purpose
STAT1 Gain-of-Function Disease
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Itacitinib
Sponsored by

About this trial
This is an expanded access trial for STAT1 Gain-of-Function Disease focused on measuring STAT1 GOF disease
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT05561985
First Posted
September 22, 2022
Last Updated
October 18, 2023
Sponsor
Incyte Corporation
1. Study Identification
Unique Protocol Identification Number
NCT05561985
Brief Title
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
Study Type
Expanded Access
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation
4. Oversight
5. Study Description
Brief Summary
Expanded access use of Itacitinib to treat a single patient with aplastic anemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
STAT1 Gain-of-Function Disease
Keywords
STAT1 GOF disease
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Itacitinib
Other Intervention Name(s)
INCB039110
10. Eligibility
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Incyte Corporation Call Center (US)
Phone
1.855.463.3463
Email
medinfo@incyte.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Forbes Satter, MD
Organizational Affiliation
Baylor College of Medicine - Texas Children's Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
We'll reach out to this number within 24 hrs